Research
Hormonal
Oestrogen receptor alpha (ERα) activation mediates the protective effects of oestrogens on metabolic health by promoting insulin synthesis, beta-cell survival, and energy expenditure through brown adipose tissue beiging.
The protective benefits of oestrogen in women are largely driven by its interaction with specific receptors (ERα) in key metabolic organs. This interaction helps protect the pancreas, improves how muscles use insulin, and boosts energy burning in fat tissue. This highlights why maintaining hormonal balance is crucial for metabolic health.
GoodSupportsHIGH confidence
Clinical and experimental observations evidence the protective actions of endogenous oestrogens, mainly through oestrogen receptor α activation in various tissues, including the brain, the liver, skeletal muscle, adipose tissue and pancreatic beta cells.
Why this rating
Based on animal models and mechanistic studies.
Source
Sex differences in metabolic regulation and diabetes susceptibility
Blandine Tramunt et al. · Diabetologia · 2019
DOI 10.1007/s00125-019-05040-3
narrative_reviewCited 883×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Men have a higher prevalence of type 2 diabetes than women, particularly in middle-aged populations, due to greater visceral adiposity, ectopic fat accumulation, and lower insulin sensitivity.Strong
- Endogenous oestrogens protect premenopausal women from type 2 diabetes by promoting subcutaneous fat storage, enhancing insulin sensitivity, and preserving beta-cell function, whereas the loss of oestrogen during menopause eliminates this protection and increases diabetes risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →